Protego gets $130M for AL amyloidosis drug from leaders behind Vyndaqelnews2025-12-01T11:00:24+00:00December 1st, 2025|Endpoints News|
Generate:Biomedicines to start Phase 3 studies for TSLP antibodynews2025-12-01T11:00:16+00:00December 1st, 2025|Endpoints News|
Novo’s MFN prices to supersede IRA prices for Ozempic, Wegovy, CMS saysnews2025-11-26T19:14:48+00:00November 26th, 2025|Endpoints News|
Lundbeck backs out of bidding war for sleep disorder biotech Avadelnews2025-11-26T18:11:34+00:00November 26th, 2025|Endpoints News|
Novo submits high-dose Wegovy for FDA approval using vouchernews2025-11-26T17:45:45+00:00November 26th, 2025|Endpoints News|
Delayed panel on vaccine injury payments to meet next monthnews2025-11-26T16:44:30+00:00November 26th, 2025|Endpoints News|
Imfinzi’s latest label expansion; FDA seeks more information on BiomX’s nebulizernews2025-11-26T15:30:32+00:00November 26th, 2025|Endpoints News|
FDA pushes back Ascendis’ dwarfism drug decision date by three monthsnews2025-11-26T13:57:06+00:00November 26th, 2025|Endpoints News|
China’s Zhongmou seeks to create a ‘one-size-fits-all’ rival to Luxturnanews2025-11-26T13:31:07+00:00November 26th, 2025|Endpoints News|
Cormorant eyes another $400M healthcare fundnews2025-11-26T13:02:16+00:00November 26th, 2025|Endpoints News|
